Skip Navigation
Print This Page
Share this page: More

Search Results

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (Nivolumab, BMS 936558) and the Combination of Nivolumab and Ipilimumab in Subjects with Relapsed or Refractory Hematologic Malignancy
Protocol Number:
Phase I
Ivan Borrello
This research is being done to to test the effectiveness, safety, and tolerability of an experimental drug called BMS-936558. BMS wants to find out what effect, good or bad, the study drug has on men and women with multiple myeloma, chronic myelogenous leukemia (CML), Hodgkin lymphoma, primary mediastinal B cell lymphoma (PMBL) or other B or T cell lymphomas. We also want to know if the study drug helps improve the symptoms of multiple myeloma, CML, or lymphoma,and what effect the study drug can have on your body's immune response to your tumor and how your body's immune response may change over the course of your study treatment
Subjects must have diagnosis of: relapsed or refractory B cell lymphoma, primary mediastinal B cell Lymphoma (PMBL), T cell lymphoma, Multiple Myeloma (MM), Hodgkin Lymphoma (HL), or Chronic Myeloind Leukemia Absolute neutrophil count must be greater than 1000/μL and platelet count greater than 50,000/μL. Subjects with myelodysplasia, polycythemia vera, idiopathic thrombocythemia, myelofibrosis, acute leukemias, blast phase CML, T cell lymphoblastic or Burkitt lymphoma are excluded. Subjects with autoimmune disorders are excluded.
Subjects will receive BMS-936558 by intravenous infusion every 2 weeks for up to two years depending upon response.
Last Update
09/19/2014 04:03 AM

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers


Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424



© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer